Business
Crescita Therapeutics Inc. Announces Intention to Make Normal Course Issuer Bid
Crescita Therapeutics Inc. Announces Intention to Make Normal Course Issuer Bid Ca...
About this update from Crescita Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nCrescita Therapeutics Inc. Announces Intention to Make Normal Course Issuer Bid\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nLAVAL, QC, June 17, 2019\n\n\n\nLAVAL, QC, June 17, 2019 /CNW/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (\"Crescita\" or the \"Company\"), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, announced today that it intends to make a normal course issuer bid (\"NCIB\") for a portion of its common shares (\"Common Shares\") as appropriate opportunities arise from time to time. The Company's normal course issuer bid, which is expected to be for up to 1,000,000 common shares, or approximately 6% of its public float, will be made in accordance with the requirements of the Toronto Stock Exchange (the \"TSX\") and remains subject to TSX approval. Further details regarding the NCIB will be provided following TSX approval. The Company believes that purchases of Common Shares at prices below the Company's view of its intrinsic value are in the best interests of the Company and a desirable use of the Company's capital. \n\n \n \n\n \nThe Company also announced today that it intends to adopt an automatic securities purchase plan in connection with the NCIB that contains strict parameters regarding how its Common Shares may be repurchased during times when it would ordinarily not be permitted to purchase Common Shares due to regulatory restrictions or self-imposed blackout periods. \nAbout Crescita Therapeutics Inc.Crescita (TSX: CTX and OTC US: CRRTF) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. Ple...